000999:SZSEChina Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Analysis
Data as of 2026-03-07 - not real-time
CN¥30.16
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
China Resources Sanjiu is trading just below its short‑term resistance of ~30.17 CNY, with the price at 30.16 CNY and a bullish MACD histogram, while the RSI of 68 signals a near‑overbought condition. Technical momentum remains positive as the stock sits above its 20‑day (≈28.94) and 50‑day (≈28.72) moving averages, and the ultra‑low beta of 0.05 suggests minimal market‑wide volatility, though volume has been tapering.
Fundamentally, the company delivers strong top‑line growth at 22% YoY, a healthy operating margin of ~15% and ROE near 11%, while trading at a PE of 18 against an industry average of 25 and a forward PE of 12, indicating a clear valuation discount. The 4.86% dividend yield, backed by a 61% payout ratio and a net cash position of over 8.5 B CNY, points to sustainable shareholder returns, making the stock appear undervalued with a blend of growth and value attributes.
Fundamentally, the company delivers strong top‑line growth at 22% YoY, a healthy operating margin of ~15% and ROE near 11%, while trading at a PE of 18 against an industry average of 25 and a forward PE of 12, indicating a clear valuation discount. The 4.86% dividend yield, backed by a 61% payout ratio and a net cash position of over 8.5 B CNY, points to sustainable shareholder returns, making the stock appear undervalued with a blend of growth and value attributes.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near technical resistance
- High RSI indicating overbought pressure
- Bullish MACD supporting upside potential
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Robust revenue growth of ~22%
- Attractive valuation relative to peers
- Strong dividend yield with solid cash balance
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Sustained cash generation and low leverage
- Demographic and healthcare demand in China
- Consistent dividend policy enhancing total return
Key Metrics & Analysis
Financial Health
Revenue Growth22.40%
Profit Margin10.82%
P/E Ratio18.2
ROE10.93%
Debt/Equity14.69
P/B Ratio2.4
Op. Cash FlowCN¥0
Free Cash FlowCN¥0
Industry P/E25.1
Technical Analysis
TrendNeutral
RSI68.3
SupportCN¥27.82
ResistanceCN¥30.17
MA 20CN¥28.94
MA 50CN¥28.72
MA 200CN¥29.94
MACDBullish
VolumeDecreasing
Fear & Greed Index68.77
Valuation
Target PriceCN¥37.49
Upside/Downside24.31%
GradeUndervalued
TypeBlend
Dividend Yield4.86%
Risk Assessment
Beta0.05
Volatility19.00%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.